DPP4 and hepatocellular carcinoma: Our results suggested that the effect of DPP-4 inhibitors on the risk of HCC in adult patients with type 2 DM and chronic HCV infection may be related to the use, dosage and therapeutic duration of DPP-4 inhibitor treatment.